Daiichi Sankyo Company Limited, a global pharmaceutical company, announced that its wholly owned subsidiary, Daiichi Sankyo Korea Co., Ltd. (DSKR) headquarters at Jongno-gu, Seoul, South Korea, and Daewoong Pharmaceutical Co., Ltd. (Daewoong Pharmaceutical) headquarters at Gangnam-gu, Seoul, South Korea have signed an agreement for the co-promotion of the oral, once-daily anti-coagulant, Lixiana (generic name: edoxaban).

Daewoong Pharmaceutical is also the co-promotion partner in South Korea for the Daiichi Sankyo antihypertensives Olmetec, Olmetec Plus, Sevikar, Sevikar HCT, and through this new agreement, Daiichi Sankyo Korea aims to maximise Lixiana’s product value and further contribute to disease treatment and prevention in South Korea.

Lixiana was approved in South Korea in August 2015 and will be launched within this fiscal year.

Established in 1945, Daewoong Pharmaceutical Co., Ltd. has the largest prescription drug sales in Korea and envisions itself to become a top 50 global healthcare company by 2020.